ICICI Pru Nifty Pharma Index Fund(IDCW Payout)
Ticker: mf17397
Decent
66/100
☆ Add to Watchlist
More Options
I
ICICI Pru Nifty Pharma Index Fund(IDCW)
The fund is positioned well within the pharma sector, showing decent growth potential but with some risks involved.
View details
A
Aditya Birla SL US Treasury 1-3 year Bond ETFs FoF(IDCW Reinvest)
The fund is a conservative investment with low growth potential, suitable for risk-averse investors.
View details
A
Aditya Birla SL US Treasury 1-3 year Bond ETFs FoF(IDCW)
The fund shows moderate potential with stable returns but lacks strong growth catalysts.
View details
K
Kotak International REIT Overseas Equity Omni FOF(IDCW)
The fund shows several weaknesses in growth and profitability metrics, indicating a risky investment at this time.
View details
K
Kotak International REIT Overseas Equity Omni FOF(IDCW Payout)
The fund shows potential for moderate growth, but investors should be cautious due to execution risks and valuation concerns.
View details
L
LIC MF Healthcare Fund(IDCW)
The LIC MF Healthcare Fund shows decent potential with strong growth and profitability metrics, but some execution risks need to be monitored.
View details
P
PGIM India Corp Bond Fund(M-IDCW)
The fund shows decent stability but lacks strong growth drivers. Investors should be cautious.
View details
P
PGIM India Corp Bond Fund(Q-IDCW)
The fund shows decent potential but is hindered by inconsistent growth and average profitability metrics.
View details
P
PGIM India Corp Bond Fund(A-IDCW)
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
T
Tata Nifty Auto Index Fund(IDCW Payout)
The Tata Nifty Auto Index Fund shows decent potential but faces challenges in profitability and valuation. Investors should be cautious and monitor market developments closely.
View details
T
Tata Nifty Auto Index Fund(IDCW)
The Tata Nifty Auto Index Fund shows potential with a decent score, but investors should be cautious of market volatility and execution risks.
View details
L
LIC MF BSE Sensex Index Fund(IDCW)
The LIC MF BSE Sensex Index Fund shows decent potential with a diversified portfolio and consistent growth, but investors should be cautious of valuation and governance aspects.
View details
3
360 ONE ELSS Tax Saver Nifty 50 Index Fund(IDCW)
The fund shows a decent investment opportunity with stable growth and profitability metrics, though some risks remain due to market conditions.
View details
D
DSP Nifty SDL Plus G-Sec Sep 2027 50:50 Index Fund(IDCW)
The fund offers stability but lacks significant growth potential, making it a risky investment for aggressive investors.
View details
S
SBI FMP-79-1130D(IDCW)
The stock presents a decent investment opportunity but with notable risks and limited growth potential.
View details
M
Mirae Asset Nifty AAA PSU Bond Plus SDL Apr 2026 50:50 Index Fund(IDCW)
The fund shows moderate potential but is hindered by inconsistent profitability and limited growth drivers.
View details
Business Overview
The ICICI Pru Nifty Pharma Index Fund is designed for investors looking to capitalize on the growth potential of the Indian pharmaceutical sector. This fund tracks the Nifty Pharma Index, offering exposure to top pharma companies in India. It's ideal for those seeking a systematic investment approach with a focus on long-term wealth creation. By investing in this fund, you gain a diversified portfolio that reflects the performance of the thriving pharma industry, making it a smart choice for both new and seasoned investors.
- Tracks Nifty Pharma Index for targeted exposure
- Ideal for long-term wealth creation
- Diversified portfolio of top pharma companies
- Systematic investment option for steady growth
- Suitable for both new and experienced investors
Investment Thesis
ICICI Pru Nifty Pharma Index Fund presents a compelling investment opportunity due to its strong backing from the ICICI Group, a credible promoter. The fund stands to benefit from the growing digital services landscape in the pharma sector, and its attractive valuation compared to peers makes it a prudent choice for investors seeking exposure in this space.
- Strong promoter group: Backed by the reputable ICICI Group.
- Growth runway: Digital services in the pharma sector are expanding rapidly.
- Attractive valuation: Positioned favorably compared to industry peers.
- Diversified exposure: Invests in a broad range of leading pharma companies.
- Long-term potential: Capitalizes on the increasing demand for healthcare solutions.
Opportunity vs Risk
Opportunities
- Growing pharmaceutical sector in India
- Potential for high returns
- Diversification through index fund
- Increased healthcare spending
- Strong government support for pharma
Risks ⚠️
- Market volatility affecting returns
- Regulatory changes impact sector
- Currency fluctuations risk
- High competition in pharma
- Economic downturn impacts demand
Peer Perspective
ICICI Pru Nifty Pharma Index Fund trades at a slight premium compared to peers like Nippon India Pharma Fund and HDFC Pharma Fund. A rerating could occur with improved margin stability and consistent growth in the sector.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Nifty Pharma Index Fund(IDCW Payout) • Updated: 2025-10-01 03:21:00
-
10BusinessHighPharma sector is essential and growing, but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is stable, but some concerns over disclosures.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 66 / 100
• Decent
The fund is positioned in a growing sector with decent growth prospects, but faces challenges in profitability and valuation metrics.